Carlos A. Vargas, MD, discusses updated survival outcomes, safety, and the mechanism of SYNC-T SV-102, an investigational in situ immunotherapy for metastatic prostate cancer.
|Videos|January 20, 2021
Analysis underscores importance of pretreatment urine cultures in patients with recurrent UTI
Author(s)Urology Times staff
Investigators evaluated uropathogen prevalence and antibiotic resistance in a urogynecologic patient population.
Advertisement
In this interview, Megan S. Bradley, MD, discusses findings from the recent Neurourology and Urodynamics paper, Sporadic compared to recurrent urinary tract infections: Considerations for urogynecologic patients, for which she served as a study author. Bradley is an assistant professor in the department of obstetrics, gynecology, and reproductive sciences at the University of Pittsburgh.
Advertisement
Related to this article
Kim Chi, MD, FRCPC, discusses the rationale and design of the phase 3 KLK2-comPAS trial evaluating pasritamig alone and in combination with JNJ-9401 in patients with mCRPC.
Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.
Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.
Jeffrey M. Spier, MD, reviews evidence on ARPI dose reduction in prostate cancer and discusses monitoring treatment response, tolerability, and dose reescalation.
Jeffrey M. Spier, MD, discusses managing ARPI-related fatigue through dose adjustments, patient monitoring, and strategies to maintain treatment adherence.
Sandip M. Prasad, MD, MPhil, discusses the safety profile of mitomycin intravesical solution, including common adverse events and patient counseling during chemoablation for NMIBC.
Sandip M. Prasad, MD, MPhil, discusses 3-year ENVISION trial data showing durable responses with mitomycin intravesical solution for recurrent LG-IR-NMIBC.
Advertisement
Advertisement
Trending on Urology Times
1
Adding darolutamide to ADT and radiation improves MFS in very high-risk localized prostate cancer
2
PROTEUS Substudy: Perioperative apalutamide plus ADT improves EFS vs surgery alone
3
VOLGA: Durvalumab plus enfortumab vedotin improves EFS, OS in MIBC
4
In situ immunotherapy shows encouraging survival findings in prostate cancer
5